1,773 reports of this reaction
2.0% of all FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE reports
#8 most reported adverse reaction
PRODUCT COMPLAINT is the #8 most commonly reported adverse reaction for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 1,773 FDA adverse event reports linking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE to PRODUCT COMPLAINT. This represents approximately 2.0% of all 88,399 adverse event reports for this drug.
Patients taking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE who experience product complaint should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT COMPLAINT is a less commonly reported adverse event for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, but still significant enough to appear in the safety profile.
In addition to product complaint, the following adverse reactions have been reported for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE:
The following drugs have also been linked to product complaint in FDA adverse event reports:
PRODUCT COMPLAINT has been reported as an adverse event in 1,773 FDA reports for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT COMPLAINT accounts for approximately 2.0% of all adverse event reports for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, making it a notable side effect.
If you experience product complaint while taking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.